ArticleFrontiers in oncology2025
Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03950154 (Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte (PD1-T) Combined With XELOX and Bevacizumab in the First-line Treatment of Recurrent and Metastatic Colorectal Cancer
Who cites it
2 citing papers in PubMed.
- Psychometric properties comparison of EQ-5D-Y-3L and CHU-9D in children with adenoid hypertrophy.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cost-effectiveness of finotonlimab plus chemotherapy versus chemotherapy alone for recurrent or metastatic head and neck cancer in China.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the cost-effectiveness of adoptive cellular immunotherapy (ACI) combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer (mCRC) and provide evidence-based support for drug pricing strategies. Methods: A Markov model was constructed using data from the NCT03950154 phase III clinical trial, which randomized 202 patients into two groups: ACI combined with oxaliplatin/capecitabine/bevacizumab (n=100) and chemotherapy alone (n=102). Clinical outcomes, including progression-free survival (PFS), overall survival (OS), and adverse events, were analyzed. Costs, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) were calculated from the perspective of the Chinese healthcare system. Probabilistic sensitivity analysis was employed to assess model stability, accompanied by scenario analysis, with price simulations conducted under three willingness-to-pay (WTP) thresholds (1.5×, 1.94×, and 3× China's per capita gross domestic product [GDP]). Results: The ACI group demonstrated superior clinical outcomes compared to chemotherapy alone, with a median PFS of 14.8 vs. 9.9 months (hazard ratio [HR]=0.60, p=0.009) and a median OS not reached vs. 25.6 months (HR=0.57, p=0.043). Over a 20-year simulation, the ACI group provided an additional 1.72 QALY, yielding an ICER of $35,881.71/QALY. At the base-case price ($6,819.45 per cycle), ACI remained cost-effective within China's WTP threshold ($36,721.86/QALY). Scenario analysis revealed that extending the simulation time horizon to 10 and 15 years reduced the ICER to $40,804.77/QALY and $37,770.23/QALY, respectively. Systematic cross-validation of 2,448 model combinations (72 control group/34 ACI group survival curves) indicated that 71.84% of scenarios met predefined cost-effectiveness criteria (ICER range: $22,204 - $58,360/QALY). Price sensitivity analysis further demonstrated that cost-effectiveness advantages persisted when ACI cycle costs were reduced to $1,670.33 (corresponding to WTP=1.5×GDP=$18,360.93), $3,271.06 (corresponding to WTP = 1.94×GDP = $23,746.80), and $7,098.9 (corresponding to WTP = 3×GDP = $36,721.86). Conclusion: At current pricing, ACI combined with chemotherapy provides significant clinical and economic benefits for Chinese mCRC patients, with cost-effectiveness validated through multidimensional scenario analyses and model evaluations. Further evidence is required to validate and refine the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.